Commercialisation grants receive overhaul
08 December, 2011 by Staff WritersEarly Stage Commercialisation grants no longer have to be repaid and larger companies can now apply for the grants.
AusBiotech WA Committee welcomes new additions
08 December, 2011 by AusBiotechAusBiotech has welcomed two new appointments to the West Australian Branch Committee and named the new Chair, Mr Brian Leedman.
Strong results from Biotron HCV trial
08 December, 2011 by Dylan Bushell-EmblingNearly 90% of patients treated with Biotron's (ASX:BIT) Hepatitis C treatment candidate demonstrated a complete EVR at three month follow-up.
Govt tips extra $100m into innovation VC fund
08 December, 2011 by Dylan Bushell-EmblingAustralian biotechs will have access to a slice of $200m in startup funding, from VC firms applying for the latest tranche of the government's Innovation Investment Fund.
Margaret Sheil steps down from ARC
06 December, 2011 by Tim DeanAustralian Research Council CEO Professor Margaret Sheil will leave the ARC in April 2012 to take up position as University of Melbourne Provost.
Industry thought leaders to determine policy direction
06 December, 2011 by AusBiotechAusBiotech will host two consultation policy fora in its Policy Summit of industry thought leaders this week to determine public policy direction in regard to biotechnology and medical technology for the coming one to three years.
Academy Awards (for science) announced
06 December, 2011 by Tim DeanSeveral leading life scientists have landed Australian Academy of Science awards for scientific excellence.
Trial demonstrates long life tissue heart valves
05 December, 2011 by Dylan Bushell-EmblingTissue treated with Allied Healthcare Group's ADAPT tissue engineering technology showed significantly reduced calcification in preclinical trials.
Patrys raises $3.4m to fund product trials
05 December, 2011 by Dylan Bushell-EmblingCancer treatment development company Patrys (ASX:PAB) has raised $3.4m in an oversubscribed placement to fund clinical trials for its antibody-based products.
News in movers and shakers
05 December, 2011 by Dylan Bushell-EmblingCBio appoints new chairman, interim MD; AusBiotech CEO joins Research Australia board; Timothy Waugh named Hatchtech CEO.
Manufacturing taskforce an opportunity for life science sector
01 December, 2011 by Tim DeanAusBiotech will be lobbying for a greater emphasis on biopharma and medical devices on the newly established Prime Minister's Taskforce on Manufacturing.
Victorian Government establishes Biotechnology Advisory Council
01 December, 2011 by Tim DeanBiotechnology Advisory Council will advise the government on current and emerging opportunities and threats to the biotechnology sector and aid in implementation of policy.
AstraZeneca invests in Victoria's NeuProtect
01 December, 2011 by Dylan Bushell-EmblingVictorian biopharma NeuProtect has added AstraZeneca's venture capital subsidiary, MedImmune Ventures, as a new investor.
AusBiotech CEO appointed to Research Australia Board
01 December, 2011 by AusBiotechAusBiotech CEO, Dr Anna Lavelle, has been appointed to the Board of Research Australia, effective from the annual general meeting held recently.
Immuron signs distribution deal worth up to $113 million
29 November, 2011 by Dylan Bushell-EmblingImmuron (ASX:IMC) has secured a multi-market distribution deal worth up to C$115.5 million ($112.7m) for its debut OTC antibody product, Travelan.
